{"gene":"IL7R","run_date":"2026-04-28T18:06:54","timeline":{"discoveries":[{"year":1998,"finding":"Loss-of-function mutations in IL7R cause T(-)B(+)NK(+) SCID, demonstrating that IL-7Rα signaling is required for human T-cell development but not NK-cell development, and that the T-cell (but not NK-cell) defect in X-linked SCID results from inactivation of IL-7Rα signaling.","method":"Genetic identification of IL7R mutations in SCID patients; comparison of T, B, NK cell phenotypes across SCID genotypes","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — definitive loss-of-function human genetics with clear cellular phenotype; foundational paper with >600 citations","pmids":["9843216"],"is_preprint":false},{"year":2007,"finding":"A SNP (rs6897932) in alternatively spliced exon 6 of IL7R influences the ratio of soluble to membrane-bound IL-7Rα isoforms by disrupting an exonic splicing silencer, thereby affecting IL-7R signaling levels and multiple sclerosis risk.","method":"Functional SNP analysis; alternative splicing assays measuring soluble vs. membrane-bound isoform ratios","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — functional splicing assay with replicated genetic association across four independent cohorts","pmids":["17660817"],"is_preprint":false},{"year":2011,"finding":"Somatic gain-of-function IL7R mutations in T-ALL (mostly in exon 6) introduce unpaired cysteines in the extracellular juxtamembrane-transmembrane region, promoting de novo intermolecular disulfide bonds between mutant IL-7Rα subunits and driving constitutive JAK1 signaling independently of IL-7, γc, or JAK3, leading to cell transformation and tumor formation.","method":"Biochemical assays (disulfide bond formation), signaling assays (JAK1 phosphorylation), cell transformation assays, mutagenesis (cysteine requirement), tumor formation in mice","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 — reconstitution, mutagenesis, and in vivo transformation assays in a single landmark study; replicated by Shochat et al. same year","pmids":["21892159"],"is_preprint":false},{"year":2011,"finding":"Gain-of-function IL7R mutations in pediatric B- and T-ALL cause either S185C extracellular substitution or transmembrane domain insertions/deletions; the cysteine is essential for constitutive receptor activation; in B-cell precursor leukemias, mutant IL-7Rα forms a functional receptor with CRLF2 for TSLP signaling; these mutations confer cytokine-independent growth.","method":"Biochemical activation assays, cytokine-independent growth assays, mutagenesis confirming cysteine requirement, functional CRLF2 co-receptor assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal biochemical and functional assays with mutagenesis; independent replication of Zenatti et al.","pmids":["21536738"],"is_preprint":false},{"year":2013,"finding":"Soluble IL-7Rα (sIL7Rα) has moderate affinity for IL-7 but does not bind TSLP; sIL7Rα competes with cell-associated IL-7R to reduce excessive IL-7 consumption, thereby enhancing IL-7 bioactivity when cytokine is limited; sIL7Rα also diminishes CD95 and SOCS1 expression during IL-7 signaling and potentiates homeostatic expansion and autoimmune encephalomyelitis in murine models.","method":"Binding affinity assays (sIL7Rα vs. IL-7/TSLP), in vitro signaling assays, murine homeostatic expansion models, EAE model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vitro and in vivo assays; direct binding and functional measurements","pmids":["23610432"],"is_preprint":false},{"year":2012,"finding":"CPSF1 (cleavage and polyadenylation specificity factor 1) binds to a consensus polyadenylation signal (AAUAAA) in intron 6 of IL7R downstream of the exon 6 5' splice site and represses exon 6 inclusion; competing mRNA splicing and polyadenylation regulate the ratio of soluble to membrane-bound IL7R isoforms.","method":"RNA affinity chromatography/mass spectrometry to identify trans-acting factors; CPSF1 knockdown splicing assays; mutagenesis of polyadenylation signal","journal":"RNA (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — biochemical identification of trans-acting factor combined with mutagenesis and functional knockdown assays","pmids":["23151878"],"is_preprint":false},{"year":2017,"finding":"The RNA helicase DDX39B is a potent activator of IL7R exon 6 splicing (promoting membrane-bound isoform) and repressor of soluble IL7R production; a genetic variant in the 5' UTR of DDX39B reduces its translation and shows strong genetic and functional epistasis with IL7R exon 6 allelic variants to increase MS risk.","method":"RNA helicase functional assays, genetic association analysis, translational reporter assays, splicing minigene assays, epistasis analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — functional splicing mechanistic demonstration with genetic epistasis validated across multiple approaches","pmids":["28340352"],"is_preprint":false},{"year":2015,"finding":"IL-7 stimulation induces clathrin-mediated endocytosis of CD127 (IL-7Rα) in primary human CD8 T cells through a process dependent on lipid-raft formation and dynamin activity; internalized CD127 traffics from early endosomes (EEA1+) to late endosomes (RAB7+) and is subsequently degraded by the proteasome (20S subunit co-localization), providing a negative feedback mechanism on IL-7 signaling.","method":"Confocal microscopy with endosomal markers, inhibitor studies (clathrin, dynamin, lipid rafts), proteasome inhibition assays in primary human CD8 T cells","journal":"Immunology and cell biology","confidence":"High","confidence_rationale":"Tier 1 — direct live-cell imaging and functional inhibitor studies with multiple orthogonal markers; mechanistically complete pathway","pmids":["26272555"],"is_preprint":false},{"year":2017,"finding":"IL-7Rα undergoes polyglutamylation catalyzed by TTLL4 and TTLL13 in common helper-like innate lymphoid progenitors; this polyglutamylation triggers STAT5 activation to initiate Sall3 transcription factor expression, driving ILC3 differentiation; CCP2 deglutamylase reverses this modification, and IL-7Rα E446A mutation reduces Sall3 expression and ILC3 numbers.","method":"Enzymatic assays identifying TTLL4/TTLL13 as writers and CCP2 as eraser; IL-7Rα E446A knockin mouse; ILC3 quantification; STAT5 phosphorylation assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — PTM writer/eraser identification with mutagenesis knockin mouse and downstream signaling readout","pmids":["28794449"],"is_preprint":false},{"year":2010,"finding":"Selective disruption of the Y449xxM motif of IL-7Rα (IL-7Rα(449F) knock-in mice) prevents IL-7-mediated T- and B-lymphocyte transformation in transgenic IL-7 and Eμ-myc models, and decreases B-cell viability in bone marrow progenitors; this demonstrates that IL-7Rα Y449 signaling is specifically required for lymphocyte transformation and survival signaling.","method":"Knock-in mouse model (IL-7Rα Y449F); crossing with transgenic IL-7 and Eμ-myc lymphomagenesis models; survival/viability assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — targeted knock-in mutagenesis with in vivo genetic epistasis in lymphomagenesis models","pmids":["20440272"],"is_preprint":false},{"year":2019,"finding":"IL-7R is essential for leukemia-initiating cell (LIC) activity in T-ALL: IL-7Rα-deficient hematopoietic progenitors transduced with constitutively active Notch1 fail to generate leukemia in vivo; IL-7R expression marks T-ALL cells with LIC potential; impaired IL-7R signaling hampers engraftment of patient-derived T-ALL xenografts; IL-7R-dependent LIC activity extends to B-ALL.","method":"Loss-of-function (Il7r-deficient mice), Notch1-induced T-ALL transplantation model, patient-derived xenografts, limiting-dilution transplantation assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with defined cellular phenotype, multiple in vivo models including patient-derived xenografts","pmids":["31530562"],"is_preprint":false},{"year":2021,"finding":"Overexpression of wild-type IL-7Rα (without mutational activation) in mouse models drives thymocyte self-renewal, thymus hyperplasia, and fatal T-ALL with activation of JAK/STAT, PI3K/Akt/mTOR, and Notch signaling, with frequent PI3K/Akt hyperactivation and Bcl-2 upregulation; tumors remain sensitive to IL-7R-mediated signaling inhibitors.","method":"Tetracycline-inducible Il7r transgenic mice; Rosa26 IL7R knockin mice; pharmacological inhibitors (ruxolitinib, AZD1208, dactolisib, palbociclib, venetoclax); transcriptional profiling","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — two independent mouse gain-of-function models with mechanistic signaling characterization and pharmacological validation","pmids":["33970999"],"is_preprint":false},{"year":2012,"finding":"IL-7/IL-7Rα signaling maintains telomere integrity via regulation of POT1 (protection of telomere 1) expression; withdrawal of IL-7/IL-7Rα signaling diminishes POT1 protein synthesis, leading to telomere erosion, chromosomal anomalies (including Robertsonian translocations), and p53 pathway activation in developing T cells.","method":"IL-7Rα(null)p53(null) double-knockout mice; molecular analysis of POT1 expression; chromosomal and telomere analyses in thymic lymphomas; IL-7 withdrawal in IL-7-dependent p53(null) cells","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 — genetic double-KO model with molecular mechanistic follow-up (POT1 expression) and cellular phenotype","pmids":["22281704"],"is_preprint":false},{"year":2019,"finding":"IL7R interacts physically with CXCR4 to recruit BCR-ABL1 and JAK kinases in proximity, forming a molecular platform for BCR-ABL1-induced transformation in Ph+ ALL; BCR-ABL1 kinase inhibitor treatment elevates IL7R expression enabling cytokine-dependent survival; anti-IL7R antibody treatment prevents leukemia development in xenotransplantation models.","method":"Co-immunoprecipitation of IL7R/CXCR4 interaction; signaling assays; BCR-ABL1 inhibitor experiments; patient-derived xenograft models with anti-IL7R antibody","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP establishing physical interaction combined with in vivo xenograft validation","pmids":["32581241"],"is_preprint":false},{"year":2008,"finding":"IL-7R signaling contributes to thymic T regulatory (Treg) cell development: mice doubly deficient in IL-2Rβ and IL-7Rα lack CD4+Foxp3+ Tregs to the same extent as γc-deficient mice; IL-7R signaling is also required for peripheral survival of CD4+Foxp3low cells in IL-2Rβ-deficient mice.","method":"IL-2Rβ/IL-7Rα double-knockout mice; thymic reconstitution experiments; Foxp3+ Treg quantification","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic double-KO with epistasis and reconstitution experiments establishing pathway hierarchy","pmids":["18566388"],"is_preprint":false},{"year":2019,"finding":"IL-7Rα is expressed on fetal monocytes and is required for tissue-resident macrophage (trMac) development; blockade of IL-7R function during late gestation specifically impairs establishment of fetal-derived trMacs in vivo; IL-7Rα surface expression is dynamically upregulated upon transition from fetal monocyte to macrophage within fetal tissues.","method":"Il7r-Cre lineage tracing; IL-7R blockade in vivo during late gestation; fetal monocyte in vitro differentiation; IL-7Rα surface expression tracking across fetal development","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — in vivo lineage tracing with functional blockade experiments defining IL-7Rα role in myeloid development","pmids":["31332039"],"is_preprint":false},{"year":2019,"finding":"Antibody B12 against human IL-7Rα impairs IL-7/IL-7R-mediated signaling, is rapidly internalized and traffics to the lysosome upon binding, sensitizes T-ALL cells to dexamethasone, induces NK-mediated ADCC in vitro, and delays T-cell leukemia development in vivo; an B12-MMAE antibody-drug conjugate shows increased leukemia cell killing.","method":"Phage-display antibody generation; signaling assays; confocal microscopy of receptor internalization/lysosomal trafficking; in vitro ADCC assays; in vivo xenograft models; ADC efficacy assays","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays including live imaging of internalization and in vivo validation","pmids":["30850736"],"is_preprint":false},{"year":2019,"finding":"Anti-IL-7Rα monoclonal antibodies (two distinct epitopes shown by crystal structures) mediate ADCC-dependent and independent therapeutic efficacy against T-ALL patient-derived xenografts in vivo; relapsed T-ALL cells display elevated IL-7Rα expression and remain sensitive to anti-IL7Rα MAb treatment.","method":"Crystal structures of MAb-IL-7Rα complexes; ADCC assays with PDX cells; in vivo xenograft models (minimal residual and established disease)","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1 — crystal structures combined with in vivo functional validation","pmids":["31439943"],"is_preprint":false},{"year":2024,"finding":"The IL-7Rα antagonist antibody lusvertikimab (LUSV) reduces ALL burden in xenograft models via a dual mechanism: direct IL-7R antagonism and macrophage-mediated antibody-dependent cellular phagocytosis (ADCP); ADCP levels correlate with CD127 surface expression and with in vivo leukemia burden reduction.","method":"Patient-derived xenograft (PDX) models; ADCP assays; CD127 expression correlation analysis; combination with polychemotherapy in phase 2-like PDX study","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dual mode of action established with in vitro ADCP and in vivo PDX validation","pmids":["38518105"],"is_preprint":false},{"year":2019,"finding":"CD53 physically interacts with IL-7R (co-immunoprecipitation and proximity ligation) and promotes IL-7Rα surface expression; loss of CD53 reduces IL-7Rα surface expression and diminishes PI3K and JAK/STAT signaling in prepro- and pro-B cells, leading to increased B cell apoptosis and reduced B lymphopoiesis.","method":"Co-immunoprecipitation; proximity ligation assay; CD53-deficient mice; flow cytometry of IL-7Rα surface expression; signaling assays (PI3K, JAK/STAT)","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP and proximity ligation establishing physical interaction with clean KO phenotype and signaling readout","pmids":["31748347"],"is_preprint":false},{"year":2018,"finding":"JAK1 (associated with IL-7Rα) mediates signaling from gain-of-function mutant IL-7Rα; JAK1/2 inhibitor ruxolitinib inhibits ligand-independent signaling from mutant IL-7Rα and induces cell death in vitro and reduces leukemic burden in vivo; BCL-2 is an anti-apoptotic downstream mediator of IL-7R survival signaling and venetoclax (BCL-2 inhibitor) shows activity against mutant IL-7Rα-transformed cells.","method":"In vitro signaling assays with ruxolitinib; in vivo mouse leukemia model with ruxolitinib treatment; venetoclax in vitro and combination in vivo assays","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 — pharmacological pathway dissection with in vitro and in vivo validation establishing JAK1 and BCL-2 as downstream effectors","pmids":["29854301"],"is_preprint":false},{"year":2017,"finding":"In lymphatic endothelial cells, IL-7Rα signaling supports lymphatic drainage; endothelial-specific deletion of IL-7Rα impairs lymphatic drainage and increases edema during skin inflammation, while systemic IL-7 treatment exacerbates edema and immune cell infiltration despite increased drainage, showing that IL-7Rα's pro-inflammatory effects on immune cells override anti-inflammatory drainage effects.","method":"Endothelial-specific IL-7Rα knockout mice (IL-7RαΔEC); IL-7 administration to wild-type mice; IL-7Rα blocking antibody treatment; psoriasis-like inflammation model","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — clean cell-type-specific KO with defined functional phenotype; single study","pmids":["31406267"],"is_preprint":false},{"year":2017,"finding":"IL-7Rα down-regulation in zebrafish activates JAK/STAT signaling leading to apoptosis in oligodendrocytes; IL-7R is essential for myelination in embryonic and larval zebrafish.","method":"Targeted knockdown of IL-7R in zebrafish; demyelination model; JAK/STAT signaling assays; apoptosis analysis in oligodendrocytes","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — zebrafish KD with defined cellular phenotype; single study with moderate mechanistic follow-up","pmids":["28415697"],"is_preprint":false},{"year":2015,"finding":"In IL-7-stimulated CD8 T cells activated with IL12, enhanced IL-7Rα expression is critical for antitumor immunity in lymphodepleted recipients; elevated IL7Rα expression confers responsiveness to host IL-7 (not IL-15) for maximal engraftment of effector CD8 T cells.","method":"IL7Rα-deficient T cells; IL12 activation conditioning; adoptive transfer into lymphodepleted mice; antitumor efficacy assays","journal":"Cancer immunology research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic loss-of-function with defined in vivo phenotype; single study","pmids":["26297711"],"is_preprint":false},{"year":2022,"finding":"In IL7Rα-deficient T cells from Schimke immuno-osseous dysplasia (SIOD) patients, the IL7R promoter is hypermethylated (CpG methylation), leading to absent IL7Rα protein and mRNA and unresponsiveness to IL-7 stimulation; no pathogenic mutations were found in IL7R exons, implicating epigenetic silencing as the mechanism.","method":"IL7Rα protein and mRNA measurement; IL-7 stimulation assays; CpG methylation analysis of IL7R promoter; Sanger sequencing of IL7R exons","journal":"Clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct mechanistic demonstration of epigenetic regulation; single study in patient samples","pmids":["26499378"],"is_preprint":false},{"year":2018,"finding":"IL7R overexpression in esophageal squamous cell carcinoma promotes cancer cell survival; HDAC inhibitor apicidin downregulates IL7R by inducing acetylation of FOXO1, which then acts as a transcriptional repressor at the IL7R promoter, accompanied by decreased active histone modifications (ChIP assay).","method":"HDAC inhibitor (apicidin) treatment; ChIP assay for acetylated FOXO1 at IL7R promoter; histone modification analysis; IL7R knockdown anti-oncogenic effect assays","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-based mechanistic demonstration of FOXO1-mediated IL7R transcriptional repression; single study","pmids":["29749437"],"is_preprint":false},{"year":2019,"finding":"In monocytes, monocyte surface and soluble IL-7R expression are induced by LPS and strongly associate with allelic carriage of rs6897932 (disease-associated IL7R polymorphism); sIL7R production by monocytes exceeds that of CD4+ T cells; sIL7R expression additionally correlates with DDX39A (a splicing factor) expression.","method":"Protein-level genetic regulation analysis; LPS stimulation assays; flow cytometry of surface IL7R; sIL7R ELISA; genotype-protein association in healthy individuals","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — direct protein-level measurement with genotype-expression association; single study but multiple cell types and methods","pmids":["31594933"],"is_preprint":false},{"year":2022,"finding":"Loss of IL7Rα (but not Flk2) intrinsically and essentially impairs generation of tissue-resident lymphoid cells including B1a cells, marginal zone B cells, lung ILC2s, and regulatory T cells; an IL7Rα-deficient environment also selectively impairs reconstitution of these cells by wild-type HSCs, indicating both cell-intrinsic and extrinsic roles.","method":"Flk2-Cre and Il7r-Cre lineage tracing; Flk2 and IL7Rα single and double knockout mice; reciprocal transplantation experiments","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with defined phenotype and reciprocal transplantation; single study","pmids":["35072209"],"is_preprint":false},{"year":2011,"finding":"IL-7 treatment of CD4+CD25+CD127+ FoxP3+ T cells induces their phenotypic maturation into classical FoxP3+CD4+CD25hi CD127- regulatory T cells, with increased nuclear FoxP3 accumulation, CD25 upregulation, and concurrent CD127 downregulation in vitro.","method":"In vitro IL-7 treatment of sorted T cell populations; flow cytometry of CD127/CD25/FoxP3 expression; nuclear FoxP3 localization assay","journal":"Clinical and experimental immunology","confidence":"Medium","confidence_rationale":"Tier 3 — in vitro phenotypic conversion with functional readout; single lab, single study","pmids":["21413939"],"is_preprint":false},{"year":2014,"finding":"lnc-IL7R (a long noncoding RNA overlapping the 3'UTR of IL7R) suppresses LPS-induced inflammatory response by maintaining trimethylation of histone H3 at lysine 27 (H3K27me3) at the proximal promoters of inflammatory mediators (E-selectin, VCAM-1, IL-6, IL-8); knockdown of lnc-IL7R diminishes H3K27me3 and increases inflammatory gene expression.","method":"lnc-IL7R knockdown; ChIP assay for H3K27me3 at inflammatory gene promoters; LPS stimulation with cytokine/adhesion molecule measurement","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-based mechanistic demonstration; single study with two orthogonal methods","pmids":["24723426"],"is_preprint":false},{"year":2019,"finding":"IL-7R overexpression in ESCC cells (induced by direct co-culture with macrophages) promotes cancer cell survival and growth via activation of Akt and Erk1/2 signaling pathways; the IL-7/IL-7R axis also promotes ESCC cell migration through the same pathways.","method":"Co-culture of ESCC cells with macrophages; cDNA microarray; IL7R overexpression; signaling assays (Akt, Erk1/2 phosphorylation); migration assays","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function with defined downstream signaling; single study","pmids":["36672342"],"is_preprint":false},{"year":2022,"finding":"Mutant IL7R collaborates with MYC to induce early-onset T-ALL in zebrafish; mutant IL7R alone can induce T-ALL with long latency; T-ALLs co-expressing mutant IL7R and Myc show STAT5 and AKT pathway activation; mutant IL7R increases the frequency of leukemia propagating cells as shown by limiting-dilution transplantation.","method":"Stable transgenic zebrafish expressing mutant IL7R and/or Myc; limiting-dilution cell transplantation; signaling assays (STAT5, AKT); apoptosis assays","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo zebrafish genetic model with mechanistic signaling readout; single study","pmids":["35581375"],"is_preprint":false}],"current_model":"IL-7Rα (IL7R) forms a heterodimeric receptor with γc that signals constitutively through JAK1/JAK3 and STAT5/PI3K/Akt pathways to drive T-cell development, survival, and homeostasis; gain-of-function mutations introducing unpaired cysteines in the extracellular juxtamembrane-transmembrane region drive homodimerization and ligand-independent JAK1 signaling in T-ALL, while its Y449 motif specifically supports lymphocyte survival and transformation, and its expression is tightly regulated at the splicing level (exon 6 inclusion/skipping controlling membrane-bound vs. soluble isoform ratios via CPSF1 and DDX39B), at the post-translational level (clathrin/dynamin-mediated endocytosis and proteasomal degradation upon IL-7 binding), and by a novel polyglutamylation modification (by TTLL4/TTLL13, reversed by CCP2) that triggers STAT5 and Sall3-driven ILC3 development."},"narrative":{"teleology":[{"year":1998,"claim":"The fundamental question of whether IL-7Rα is required for human lymphocyte development was answered: loss-of-function IL7R mutations cause T(−)B(+)NK(+) SCID, establishing that IL-7Rα signaling is essential for T-cell but dispensable for NK-cell ontogeny.","evidence":"Identification of IL7R mutations in SCID patients with defined T/B/NK cell phenotyping","pmids":["9843216"],"confidence":"High","gaps":["Precise downstream signaling pathways mediating the T-cell developmental block were not delineated","Whether IL-7Rα contributes to non-lymphoid lineages was unknown"]},{"year":2007,"claim":"A key regulatory question—how IL-7Rα surface expression is controlled—was addressed by demonstrating that alternative splicing of exon 6 governs the ratio of membrane-bound to soluble receptor isoforms, and that a common SNP (rs6897932) disrupting an exonic splicing silencer alters this ratio and confers multiple sclerosis risk.","evidence":"Functional splicing assays with minigenes; genetic association replicated across four independent MS cohorts","pmids":["17660817"],"confidence":"High","gaps":["Trans-acting splicing factors controlling exon 6 inclusion were unidentified","How soluble IL-7Rα modulates IL-7 bioavailability in vivo was unclear"]},{"year":2008,"claim":"IL-7Rα's role was extended beyond conventional T cells to thymic regulatory T-cell development: double-deficient IL-2Rβ/IL-7Rα mice phenocopy γc deficiency for Foxp3+ Treg loss, establishing IL-7Rα as a non-redundant contributor to Treg ontogeny.","evidence":"IL-2Rβ/IL-7Rα double-knockout mice with thymic reconstitution and Foxp3+ Treg quantification","pmids":["18566388"],"confidence":"High","gaps":["Whether IL-7Rα acts at the commitment or survival stage of Treg development was not resolved","The relative quantitative contributions of IL-2 vs. IL-7 signaling to Treg generation remained unclear"]},{"year":2010,"claim":"The specific intracellular signaling motif responsible for IL-7Rα's pro-survival and transforming activity was identified: Y449F knock-in mice showed that the Y449 motif is required for IL-7-driven lymphocyte transformation and bone marrow B-cell survival.","evidence":"IL-7Rα Y449F knock-in mice crossed with transgenic IL-7 and Eμ-myc lymphomagenesis models","pmids":["20440272"],"confidence":"High","gaps":["Which specific downstream effectors (STAT5 vs. PI3K) are recruited to Y449 in vivo to mediate transformation was not separated","Whether Y449 is sufficient or merely necessary for transformation was unresolved"]},{"year":2011,"claim":"The oncogenic mechanism of IL7R mutations in T-ALL and B-ALL was elucidated: gain-of-function mutations introduce unpaired cysteines that promote receptor homodimerization via de novo disulfide bonds, driving constitutive JAK1 signaling independent of IL-7, γc, or JAK3; in B-ALL, mutant IL-7Rα partners with CRLF2 for TSLP signaling.","evidence":"Disulfide bond biochemistry, cysteine requirement by mutagenesis, cell transformation assays, tumor formation in mice (two independent studies)","pmids":["21892159","21536738"],"confidence":"High","gaps":["Structural basis for how a single cysteine substitution promotes homodimerization was not resolved at atomic resolution","Cooperating genetic events in full leukemogenesis were only partially characterized"]},{"year":2012,"claim":"Two regulatory layers of IL-7Rα were mechanistically defined: CPSF1 was identified as a trans-acting factor repressing exon 6 inclusion via intronic polyadenylation competition, and IL-7Rα signaling was shown to maintain telomere integrity through POT1 expression.","evidence":"RNA affinity chromatography/mass spectrometry with CPSF1 knockdown for splicing; IL-7Rα-null/p53-null double-KO mice with POT1 and telomere analyses","pmids":["23151878","22281704"],"confidence":"High","gaps":["Additional trans-acting splicing factors beyond CPSF1 were not identified","Whether POT1 regulation is direct (transcriptional) or indirect via STAT5 was not determined"]},{"year":2013,"claim":"The biological function of soluble IL-7Rα was clarified: sIL-7Rα binds IL-7 with moderate affinity, competes with membrane-bound receptor to preserve IL-7 bioavailability under limiting conditions, and potentiates autoimmune pathology in vivo.","evidence":"Binding affinity measurements; murine homeostatic expansion and EAE models with sIL-7Rα administration","pmids":["23610432"],"confidence":"High","gaps":["Physiological concentrations of sIL-7Rα in disease states were incompletely characterized","Whether sIL-7Rα functions as agonist or antagonist may depend on tissue IL-7 concentration, which was not fully mapped"]},{"year":2015,"claim":"The negative feedback mechanism for IL-7Rα surface expression was mapped: IL-7 binding triggers clathrin-dependent, dynamin-dependent internalization through lipid rafts, with trafficking from early to late endosomes and proteasomal degradation.","evidence":"Confocal microscopy with endosomal markers (EEA1, RAB7, 20S proteasome) and pharmacological inhibitors in primary human CD8 T cells","pmids":["26272555"],"confidence":"High","gaps":["Ubiquitin ligase(s) targeting internalized IL-7Rα for proteasomal degradation were not identified","Whether lysosomal degradation also contributes was not resolved"]},{"year":2017,"claim":"DDX39B was established as a second major trans-acting regulator of IL7R splicing: it promotes exon 6 inclusion (membrane-bound isoform), and a DDX39B 5′ UTR variant reducing its translation shows strong epistasis with the IL7R exon 6 SNP for MS susceptibility.","evidence":"Splicing minigene assays; translational reporter assays; genetic epistasis analysis","pmids":["28340352"],"confidence":"High","gaps":["Whether DDX39B acts directly on IL7R pre-mRNA or through an intermediary was not biochemically resolved","Additional helicase cofactors in the splicing complex were not identified"]},{"year":2017,"claim":"A novel post-translational modification—polyglutamylation—was discovered on IL-7Rα: TTLL4/TTLL13 catalyze this modification in innate lymphoid progenitors, triggering STAT5 activation and Sall3-driven ILC3 differentiation, while CCP2 reverses it.","evidence":"Enzymatic writer/eraser identification; IL-7Rα E446A knock-in mouse with reduced ILC3 numbers and Sall3 expression","pmids":["28794449"],"confidence":"High","gaps":["The precise glutamate residues modified and the stoichiometry of polyglutamylation were not fully mapped","How polyglutamylation mechanistically enhances JAK/STAT signaling was not determined"]},{"year":2018,"claim":"Pharmacological dissection confirmed that gain-of-function IL-7Rα mutants signal through JAK1 and upregulate BCL-2 as a critical survival effector: ruxolitinib blocks mutant signaling and venetoclax kills mutant-transformed cells.","evidence":"In vitro signaling assays and in vivo leukemia models with JAK1/2 and BCL-2 inhibitors","pmids":["29854301"],"confidence":"High","gaps":["Whether drug resistance mechanisms emerge upon prolonged JAK inhibition was not tested","Combination synergy was not systematically optimized"]},{"year":2019,"claim":"Multiple studies converged to define IL-7Rα's roles beyond classical lymphopoiesis and its therapeutic targetability: IL-7Rα marks and is required for leukemia-initiating cells in T-ALL; it is expressed on fetal monocytes and required for tissue-resident macrophage development; CD53 physically interacts with IL-7Rα to stabilize its surface expression; and anti-IL-7Rα antibodies show therapeutic efficacy via signaling blockade, ADCC, and internalization-based drug delivery.","evidence":"Il7r-KO Notch1 T-ALL model and PDX transplantation; Il7r-Cre lineage tracing with gestational blockade; Co-IP/PLA for CD53 interaction with CD53-KO mice; phage-display antibodies with crystal structures, ADCC assays, and xenograft models","pmids":["31530562","31332039","31748347","30850736","31439943","32581241"],"confidence":"High","gaps":["Whether IL-7Rα's LIC-maintaining role is signaling-dependent or expression-level-dependent is not fully separated","The structural basis for CD53-mediated stabilization of IL-7Rα at the membrane is unknown","Optimal therapeutic antibody format (naked vs. ADC vs. bispecific) is not resolved"]},{"year":2021,"claim":"Overexpression of wild-type IL-7Rα—even without activating mutations—was shown to be sufficient for thymocyte self-renewal and T-ALL development, with activation of JAK/STAT, PI3K/Akt/mTOR, and Notch pathways.","evidence":"Two independent inducible IL7R transgenic mouse models with pharmacological pathway inhibition","pmids":["33970999"],"confidence":"High","gaps":["Whether wild-type IL-7Rα overexpression requires IL-7 ligand for transformation or can signal ligand-independently at high density is not resolved","Cooperating mutations arising during leukemogenesis were not fully catalogued"]},{"year":2022,"claim":"IL-7Rα's requirement was extended to multiple tissue-resident lymphoid populations (B1a, MZ B, ILC2, Treg) via both cell-intrinsic signaling and extrinsic niche effects, and mutant IL7R was shown to cooperate with MYC in an in vivo zebrafish T-ALL model activating STAT5 and AKT.","evidence":"Il7r-Cre and Flk2-Cre lineage tracing with reciprocal transplantation in mice; transgenic zebrafish with limiting-dilution transplantation","pmids":["35072209","35581375"],"confidence":"Medium","gaps":["The molecular nature of the IL-7Rα-dependent extrinsic niche signal is unknown","Whether zebrafish IL7R mutant cooperativity with MYC translates to mammalian models remains to be tested"]},{"year":2024,"claim":"The therapeutic mechanism of anti-IL-7Rα antibody lusvertikimab was defined as dual-acting: direct receptor antagonism plus macrophage-mediated ADCP, with efficacy correlating with CD127 surface density.","evidence":"PDX models with ADCP assays and CD127 expression correlation; combination with polychemotherapy","pmids":["38518105"],"confidence":"High","gaps":["Patient selection biomarkers beyond CD127 expression are not established","Mechanisms of resistance to anti-IL-7Rα therapy are undefined"]},{"year":null,"claim":"Key unresolved questions include the atomic structure of full-length IL-7Rα homodimers formed by gain-of-function cysteine mutations, the identity of ubiquitin ligases mediating post-endocytic degradation, the precise mechanism by which polyglutamylation enhances JAK/STAT activation, and whether soluble IL-7Rα is agonistic or antagonistic in different tissue microenvironments.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length structural model of mutant IL-7Rα homodimer","Ubiquitin ligase(s) for IL-7Rα degradation not identified","Mechanistic link between polyglutamylation and STAT5 activation unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,3,8]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[13,19]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,5,6,7,19]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[7]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,4,26]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,3,8,9,11,20]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,14,15,27]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,8,15,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,3,10,11,13,31]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[9,20]}],"complexes":["IL-7R (IL-7Rα/γc heterodimer)","IL-7Rα/CRLF2 heterodimer"],"partners":["IL2RG","JAK1","JAK3","CRLF2","CD53","CXCR4","CPSF1","DDX39B"],"other_free_text":[]},"mechanistic_narrative":"IL-7Rα (encoded by IL7R) is the ligand-binding subunit of the IL-7 receptor, essential for T-cell development, B lymphopoiesis, regulatory T-cell generation, innate lymphoid cell differentiation, and tissue-resident macrophage establishment. IL-7Rα pairs with the common γ chain (γc) to signal through JAK1/JAK3–STAT5 and PI3K/Akt pathways; the intracellular Y449 motif is specifically required for lymphocyte survival and transformation, and loss-of-function IL7R mutations cause T(−)B(+)NK(+) SCID [PMID:9843216, PMID:20440272]. Gain-of-function mutations—predominantly introducing unpaired cysteines in the extracellular juxtamembrane-transmembrane region—drive ligand-independent homodimerization and constitutive JAK1 signaling that transforms T- and B-cell progenitors in acute lymphoblastic leukemia [PMID:21892159, PMID:21536738, PMID:31530562]. Receptor availability is tightly controlled at multiple levels: alternative splicing of exon 6 (regulated by CPSF1 and DDX39B) sets the ratio of membrane-bound to soluble isoforms influencing autoimmune disease risk, IL-7 binding triggers clathrin/dynamin-dependent endocytosis and proteasomal degradation, and polyglutamylation by TTLL4/TTLL13 (reversed by CCP2) activates STAT5-Sall3 signaling to direct ILC3 fate [PMID:17660817, PMID:23151878, PMID:28340352, PMID:26272555, PMID:28794449]."},"prefetch_data":{"uniprot":{"accession":"P16871","full_name":"Interleukin-7 receptor subunit alpha","aliases":["CDw127"],"length_aa":459,"mass_kda":51.6,"function":"Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P16871/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IL7R","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IL7R","total_profiled":1310},"omim":[{"mim_id":"620485","title":"TUBULIN TYROSINE LIGASE-LIKE 13; TTLL13","url":"https://www.omim.org/entry/620485"},{"mim_id":"618799","title":"CALCYPHOSINE-LIKE PROTEIN; CAPSL","url":"https://www.omim.org/entry/618799"},{"mim_id":"618738","title":"TUBULIN TYROSINE LIGASE-LIKE 4; TTLL4","url":"https://www.omim.org/entry/618738"},{"mim_id":"617345","title":"ATP/GTP-BINDING PROTEIN-LIKE 2; AGBL2","url":"https://www.omim.org/entry/617345"},{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":171.2}],"url":"https://www.proteinatlas.org/search/IL7R"},"hgnc":{"alias_symbol":["CD127","IL7RA","lnc-IL7R","IL-7Ralpha","IL7Ralpha","sIL-7R","CDw127"],"prev_symbol":[]},"alphafold":{"accession":"P16871","domains":[{"cath_id":"2.60.40.1870","chopping":"41-123","consensus_level":"high","plddt":94.504,"start":41,"end":123},{"cath_id":"2.60.40.10","chopping":"134-228","consensus_level":"high","plddt":95.5922,"start":134,"end":228}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16871","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16871-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16871-F1-predicted_aligned_error_v6.png","plddt_mean":67.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IL7R","jax_strain_url":"https://www.jax.org/strain/search?query=IL7R"},"sequence":{"accession":"P16871","fasta_url":"https://rest.uniprot.org/uniprotkb/P16871.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16871/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16871"}},"corpus_meta":[{"pmid":"16818678","id":"PMC_16818678","title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.","date":"2006","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16818678","citation_count":2120,"is_preprint":false},{"pmid":"9843216","id":"PMC_9843216","title":"Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9843216","citation_count":602,"is_preprint":false},{"pmid":"17660817","id":"PMC_17660817","title":"Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17660817","citation_count":500,"is_preprint":false},{"pmid":"26878113","id":"PMC_26878113","title":"The heterogeneity of human CD127(+) innate lymphoid cells revealed by single-cell RNA sequencing.","date":"2016","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26878113","citation_count":407,"is_preprint":false},{"pmid":"21892159","id":"PMC_21892159","title":"Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21892159","citation_count":326,"is_preprint":false},{"pmid":"22904298","id":"PMC_22904298","title":"BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22904298","citation_count":324,"is_preprint":false},{"pmid":"24631153","id":"PMC_24631153","title":"The transcription factor GATA3 is critical for the development of all IL-7Rα-expressing innate lymphoid cells.","date":"2014","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24631153","citation_count":315,"is_preprint":false},{"pmid":"31745336","id":"PMC_31745336","title":"Flip the coin: IL-7 and IL-7R in health and disease.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31745336","citation_count":296,"is_preprint":false},{"pmid":"21536738","id":"PMC_21536738","title":"Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21536738","citation_count":278,"is_preprint":false},{"pmid":"24723426","id":"PMC_24723426","title":"The human long noncoding RNA lnc-IL7R regulates the inflammatory response.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24723426","citation_count":164,"is_preprint":false},{"pmid":"26206799","id":"PMC_26206799","title":"Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.","date":"2015","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/26206799","citation_count":134,"is_preprint":false},{"pmid":"15661025","id":"PMC_15661025","title":"Interleukin-7 receptor alpha (IL-7Ralpha) deficiency: cellular and molecular bases. Analysis of clinical, immunological, and molecular features in 16 novel patients.","date":"2005","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15661025","citation_count":128,"is_preprint":false},{"pmid":"23610432","id":"PMC_23610432","title":"Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23610432","citation_count":122,"is_preprint":false},{"pmid":"18566388","id":"PMC_18566388","title":"A function for IL-7R for CD4+CD25+Foxp3+ T regulatory cells.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18566388","citation_count":119,"is_preprint":false},{"pmid":"20690182","id":"PMC_20690182","title":"Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20690182","citation_count":111,"is_preprint":false},{"pmid":"18354419","id":"PMC_18354419","title":"IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations.","date":"2008","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18354419","citation_count":102,"is_preprint":false},{"pmid":"36142322","id":"PMC_36142322","title":"The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36142322","citation_count":87,"is_preprint":false},{"pmid":"28340352","id":"PMC_28340352","title":"Human Epistatic Interaction Controls IL7R Splicing and Increases Multiple Sclerosis Risk.","date":"2017","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/28340352","citation_count":84,"is_preprint":false},{"pmid":"16492442","id":"PMC_16492442","title":"Omenn syndrome in an infant with IL7RA gene mutation.","date":"2006","source":"The Journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/16492442","citation_count":71,"is_preprint":false},{"pmid":"31332039","id":"PMC_31332039","title":"The lymphoid-associated interleukin 7 receptor (IL7R) regulates tissue-resident macrophage development.","date":"2019","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31332039","citation_count":56,"is_preprint":false},{"pmid":"20112030","id":"PMC_20112030","title":"Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility.","date":"2010","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20112030","citation_count":54,"is_preprint":false},{"pmid":"35595051","id":"PMC_35595051","title":"Significance of IL-7 and IL-7R in RA and autoimmunity.","date":"2022","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35595051","citation_count":53,"is_preprint":false},{"pmid":"19231135","id":"PMC_19231135","title":"Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients.","date":"2009","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/19231135","citation_count":51,"is_preprint":false},{"pmid":"30850736","id":"PMC_30850736","title":"A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30850736","citation_count":47,"is_preprint":false},{"pmid":"32032632","id":"PMC_32032632","title":"Optimal identification of human conventional and nonconventional (CRTH2-IL7Rα-) ILC2s using additional surface markers.","date":"2020","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32032632","citation_count":46,"is_preprint":false},{"pmid":"33970999","id":"PMC_33970999","title":"Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33970999","citation_count":45,"is_preprint":false},{"pmid":"16860834","id":"PMC_16860834","title":"HIV-specific CD8 T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memory.","date":"2006","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/16860834","citation_count":43,"is_preprint":false},{"pmid":"35243668","id":"PMC_35243668","title":"Single-cell profiling of human CD127+ innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma.","date":"2022","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/35243668","citation_count":41,"is_preprint":false},{"pmid":"21184155","id":"PMC_21184155","title":"Molecular diagnosis of severe combined immunodeficiency--identification of IL2RG, JAK3, IL7R, DCLRE1C, RAG1, and RAG2 mutations in a cohort of Chinese and Southeast Asian children.","date":"2010","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21184155","citation_count":41,"is_preprint":false},{"pmid":"27268088","id":"PMC_27268088","title":"Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27268088","citation_count":40,"is_preprint":false},{"pmid":"31530562","id":"PMC_31530562","title":"IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31530562","citation_count":39,"is_preprint":false},{"pmid":"30692988","id":"PMC_30692988","title":"Maturing Human CD127+ CCR7+ PDL1+ Dendritic Cells Express AIRE in the Absence of Tissue Restricted Antigens.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30692988","citation_count":38,"is_preprint":false},{"pmid":"23151878","id":"PMC_23151878","title":"Cleavage and polyadenylation specificity factor 1 (CPSF1) regulates alternative splicing of interleukin 7 receptor (IL7R) exon 6.","date":"2012","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23151878","citation_count":37,"is_preprint":false},{"pmid":"31594933","id":"PMC_31594933","title":"Context-specific regulation of surface and soluble IL7R expression by an autoimmune risk allele.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31594933","citation_count":36,"is_preprint":false},{"pmid":"30105620","id":"PMC_30105620","title":"Long-Term Health Outcome and Quality of Life Post-HSCT for IL7Rα-, Artemis-, RAG1- and RAG2-Deficient Severe Combined Immunodeficiency: a Single Center Report.","date":"2018","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30105620","citation_count":36,"is_preprint":false},{"pmid":"29854301","id":"PMC_29854301","title":"Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29854301","citation_count":36,"is_preprint":false},{"pmid":"30883723","id":"PMC_30883723","title":"Expression of IL-7Rα and KLRG1 defines functionally distinct CD8+ T-cell populations in humans.","date":"2019","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30883723","citation_count":36,"is_preprint":false},{"pmid":"29330114","id":"PMC_29330114","title":"Human CD4+ CD25+ CD127hi cells and the Th1/Th2 phenotype.","date":"2018","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/29330114","citation_count":35,"is_preprint":false},{"pmid":"34226281","id":"PMC_34226281","title":"Expression of KLRG1 and CD127 defines distinct CD8+ subsets that differentially impact patient outcome in follicular lymphoma.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34226281","citation_count":35,"is_preprint":false},{"pmid":"19626041","id":"PMC_19626041","title":"Variation in IL7R predisposes to sarcoid inflammation.","date":"2009","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/19626041","citation_count":33,"is_preprint":false},{"pmid":"32353080","id":"PMC_32353080","title":"Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection.","date":"2020","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/32353080","citation_count":33,"is_preprint":false},{"pmid":"27322554","id":"PMC_27322554","title":"Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27322554","citation_count":32,"is_preprint":false},{"pmid":"17595335","id":"PMC_17595335","title":"Prevention of graft-versus-host disease by anti IL-7Ralpha antibody.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17595335","citation_count":32,"is_preprint":false},{"pmid":"34615883","id":"PMC_34615883","title":"CD127+ CD94+ innate lymphoid cells expressing granulysin and perforin are expanded in patients with Crohn's disease.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34615883","citation_count":31,"is_preprint":false},{"pmid":"31439943","id":"PMC_31439943","title":"New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/31439943","citation_count":30,"is_preprint":false},{"pmid":"35303175","id":"PMC_35303175","title":"Lnc-IL7R alleviates PM2.5-mediated cellular senescence and apoptosis through EZH2 recruitment in chronic obstructive pulmonary disease.","date":"2022","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/35303175","citation_count":30,"is_preprint":false},{"pmid":"28794449","id":"PMC_28794449","title":"IL-7Rα glutamylation and activation of transcription factor Sall3 promote group 3 ILC development.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28794449","citation_count":30,"is_preprint":false},{"pmid":"27156107","id":"PMC_27156107","title":"CD4(+)CD25(+)CD127(-) and CD4(+)CD25(+)Foxp3(+) Regulatory T Cell Subsets in Mediating Autoimmune Reactivity in Systemic Lupus Erythematosus Patients.","date":"2016","source":"Archivum immunologiae et therapiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/27156107","citation_count":29,"is_preprint":false},{"pmid":"35264973","id":"PMC_35264973","title":"IL7R Is Correlated With Immune Cell Infiltration in the Tumor Microenvironment of Lung Adenocarcinoma.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35264973","citation_count":28,"is_preprint":false},{"pmid":"27206624","id":"PMC_27206624","title":"Decreased proportions of CD4 + IL17+/CD4 + CD25 + CD127- and CD4 + IL17+/CD4 + CD25 + CD127 - FoxP3+ T cells in children with autoimmune thyroid diseases (.).","date":"2016","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/27206624","citation_count":26,"is_preprint":false},{"pmid":"31255887","id":"PMC_31255887","title":"Analysis of the frequencies and functions of CD4+CD25+CD127low/neg, CD4+HLA-G+, and CD8+HLA-G+ regulatory T cells in pre-eclampsia.","date":"2019","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31255887","citation_count":26,"is_preprint":false},{"pmid":"31748347","id":"PMC_31748347","title":"The Tetraspanin CD53 Regulates Early B Cell Development by Promoting IL-7R Signaling.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/31748347","citation_count":25,"is_preprint":false},{"pmid":"30944830","id":"PMC_30944830","title":"CD4+CD25highCD127low/-FoxP3 + Regulatory T-Cell Population in Acute Leukemias: A Review of the Literature.","date":"2019","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30944830","citation_count":24,"is_preprint":false},{"pmid":"31519862","id":"PMC_31519862","title":"Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7R- Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/31519862","citation_count":24,"is_preprint":false},{"pmid":"26297711","id":"PMC_26297711","title":"Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent.","date":"2015","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/26297711","citation_count":23,"is_preprint":false},{"pmid":"21413939","id":"PMC_21413939","title":"Interleukin-7 matures suppressive CD127(+) forkhead box P3 (FoxP3)(+) T cells into CD127(-) CD25(high) FoxP3(+) regulatory T cells.","date":"2011","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21413939","citation_count":23,"is_preprint":false},{"pmid":"28446795","id":"PMC_28446795","title":"Variants in the IL7RA gene confer susceptibility to multiple sclerosis in Caucasians: evidence based on 9734 cases and 10436 controls.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28446795","citation_count":22,"is_preprint":false},{"pmid":"36705564","id":"PMC_36705564","title":"Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/36705564","citation_count":21,"is_preprint":false},{"pmid":"31817502","id":"PMC_31817502","title":"Deleterious and Oncogenic Mutations in the IL7RA.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31817502","citation_count":20,"is_preprint":false},{"pmid":"32581241","id":"PMC_32581241","title":"Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32581241","citation_count":20,"is_preprint":false},{"pmid":"22329520","id":"PMC_22329520","title":"Identification of IL7RA risk alleles for rapid progression during HIV-1 infection: a comprehensive study in the GRIV cohort.","date":"2012","source":"Current HIV research","url":"https://pubmed.ncbi.nlm.nih.gov/22329520","citation_count":20,"is_preprint":false},{"pmid":"39952598","id":"PMC_39952598","title":"The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma.","date":"2025","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/39952598","citation_count":19,"is_preprint":false},{"pmid":"31741754","id":"PMC_31741754","title":"Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.","date":"2019","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/31741754","citation_count":19,"is_preprint":false},{"pmid":"30988066","id":"PMC_30988066","title":"Notch signaling pathway regulates CD4+CD25+CD127dim/- regulatory T cells and T helper 17 cells function in gastric cancer patients.","date":"2019","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/30988066","citation_count":19,"is_preprint":false},{"pmid":"22281704","id":"PMC_22281704","title":"IL-7Rα deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis.","date":"2012","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/22281704","citation_count":18,"is_preprint":false},{"pmid":"38889332","id":"PMC_38889332","title":"Human CD127 negative ILC2s show immunological memory.","date":"2024","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38889332","citation_count":18,"is_preprint":false},{"pmid":"22227963","id":"PMC_22227963","title":"Unusual timing of CD127 expression by mouse uterine natural killer cells.","date":"2012","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/22227963","citation_count":17,"is_preprint":false},{"pmid":"26499378","id":"PMC_26499378","title":"Lack of IL7Rα expression in T cells is a hallmark of T-cell immunodeficiency in Schimke immuno-osseous dysplasia (SIOD).","date":"2015","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/26499378","citation_count":17,"is_preprint":false},{"pmid":"27807805","id":"PMC_27807805","title":"Identification of Heterozygous Single- and Multi-exon Deletions in IL7R by Whole Exome Sequencing.","date":"2016","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27807805","citation_count":17,"is_preprint":false},{"pmid":"35693814","id":"PMC_35693814","title":"Human CD4+CD25+CD226- Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4+CD25+CD127lo/- Tregs for Adoptive Cell Therapy.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35693814","citation_count":17,"is_preprint":false},{"pmid":"28284938","id":"PMC_28284938","title":"Human IL-6RhiTIGIT- CD4+CD127lowCD25+ T cells display potent in vitro suppressive capacity and a distinct Th17 profile.","date":"2017","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/28284938","citation_count":17,"is_preprint":false},{"pmid":"26272555","id":"PMC_26272555","title":"IL-7 induces clathrin-mediated endocytosis of CD127 and subsequent degradation by the proteasome in primary human CD8 T cells.","date":"2015","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26272555","citation_count":17,"is_preprint":false},{"pmid":"37231145","id":"PMC_37231145","title":"PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells.","date":"2023","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37231145","citation_count":16,"is_preprint":false},{"pmid":"27760802","id":"PMC_27760802","title":"CD127 Expression in Naive and Memory T Cells in HIV Patients Who Have Undergone Long-Term HAART.","date":"2016","source":"Laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27760802","citation_count":16,"is_preprint":false},{"pmid":"35581375","id":"PMC_35581375","title":"Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia.","date":"2022","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/35581375","citation_count":15,"is_preprint":false},{"pmid":"37562671","id":"PMC_37562671","title":"BMI1-induced CD127+KLRG1+ memory T cells enhance the efficacy of liver cancer immunotherapy.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37562671","citation_count":15,"is_preprint":false},{"pmid":"31406267","id":"PMC_31406267","title":"Opposing roles of endothelial and leukocyte-expressed IL-7Rα in the regulation of psoriasis-like skin inflammation.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31406267","citation_count":14,"is_preprint":false},{"pmid":"29749437","id":"PMC_29749437","title":"Oncogenic IL7R is downregulated by histone deacetylase inhibitor in esophageal squamous cell carcinoma via modulation of acetylated FOXO1.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29749437","citation_count":14,"is_preprint":false},{"pmid":"32218692","id":"PMC_32218692","title":"Expression of CD4+CD25+CD127Low regulatory T cells and cytokines in peripheral blood of patients with primary liver carcinoma.","date":"2020","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32218692","citation_count":14,"is_preprint":false},{"pmid":"32111053","id":"PMC_32111053","title":"Association of Multiple Sclerosis Phenotypes with Single Nucleotide Polymorphisms of IL7R, LAG3, and CD40 Genes in a Jordanian Population: A Genotype-Phenotype Study.","date":"2020","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/32111053","citation_count":14,"is_preprint":false},{"pmid":"21190413","id":"PMC_21190413","title":"Variation in SNPs of the IL7Ra gene is associated with multiple sclerosis in the Iranian population.","date":"2010","source":"Immunological investigations","url":"https://pubmed.ncbi.nlm.nih.gov/21190413","citation_count":13,"is_preprint":false},{"pmid":"32780913","id":"PMC_32780913","title":"Impaired lnc-IL7R modulatory mechanism of Toll-like receptors is associated with an exacerbator phenotype of chronic obstructive pulmonary disease.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32780913","citation_count":13,"is_preprint":false},{"pmid":"29449560","id":"PMC_29449560","title":"Knockout of zebrafish interleukin 7 receptor (IL7R) by the CRISPR/Cas9 system delays retinal neurodevelopment.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29449560","citation_count":13,"is_preprint":false},{"pmid":"38518105","id":"PMC_38518105","title":"The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/38518105","citation_count":13,"is_preprint":false},{"pmid":"27729062","id":"PMC_27729062","title":"Screening for peptides targeted to IL-7Rα for molecular imaging of rheumatoid arthritis synovium.","date":"2016","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27729062","citation_count":13,"is_preprint":false},{"pmid":"25007250","id":"PMC_25007250","title":"CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25007250","citation_count":13,"is_preprint":false},{"pmid":"26770543","id":"PMC_26770543","title":"Expression and significance of CD4(+)CD25(+)CD127(-) regulatory T cells in peripheral blood of patients with different phenotypes of Guillain-Barré syndrome.","date":"2015","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26770543","citation_count":13,"is_preprint":false},{"pmid":"21543551","id":"PMC_21543551","title":"Relevance of IL7R genotype and mRNA expression in Dutch patients with multiple sclerosis.","date":"2011","source":"Multiple sclerosis (Houndmills, Basingstoke, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21543551","citation_count":12,"is_preprint":false},{"pmid":"28415697","id":"PMC_28415697","title":"Down-regulation of interleukin 7 receptor (IL-7R) contributes to central nervous system demyelination.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28415697","citation_count":12,"is_preprint":false},{"pmid":"20440272","id":"PMC_20440272","title":"Selective ablation of the YxxM motif of IL-7Ralpha suppresses lymphomagenesis but maintains lymphocyte development.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20440272","citation_count":12,"is_preprint":false},{"pmid":"23888080","id":"PMC_23888080","title":"Downregulation of IL7R, CCR7, and TLR4 in the cord blood of children with respiratory syncytial virus disease.","date":"2013","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/23888080","citation_count":12,"is_preprint":false},{"pmid":"30995946","id":"PMC_30995946","title":"TCR activation mimics CD127lowPD-1high phenotype and functional alterations of T lymphocytes from septic shock patients.","date":"2019","source":"Critical care (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30995946","citation_count":12,"is_preprint":false},{"pmid":"28404633","id":"PMC_28404633","title":"IL-7Rα Expression Regulates Murine Dendritic Cell Sensitivity to Thymic Stromal Lymphopoietin.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28404633","citation_count":12,"is_preprint":false},{"pmid":"35072209","id":"PMC_35072209","title":"IL7Rα, but not Flk2, is required for hematopoietic stem cell reconstitution of tissue-resident lymphoid cells.","date":"2022","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35072209","citation_count":11,"is_preprint":false},{"pmid":"21161391","id":"PMC_21161391","title":"Association between the IL7R T244I polymorphism and multiple sclerosis: a meta-analysis.","date":"2010","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21161391","citation_count":11,"is_preprint":false},{"pmid":"23069254","id":"PMC_23069254","title":"Somatic mutation of IL7R exon 6 in acute leukemias and solid cancers.","date":"2012","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23069254","citation_count":11,"is_preprint":false},{"pmid":"33579907","id":"PMC_33579907","title":"CHBP induces stronger immunosuppressive CD127+ M-MDSC via erythropoietin receptor.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33579907","citation_count":11,"is_preprint":false},{"pmid":"32203694","id":"PMC_32203694","title":"Macrophages represent the major pool of IL-7Rα expressing cells in patients with myocarditis.","date":"2020","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/32203694","citation_count":11,"is_preprint":false},{"pmid":"34575268","id":"PMC_34575268","title":"Characterization of Circulating IL-7R Positive Cell Populations for Early Detection of Pancreatic Ductal Adenocarcinoma.","date":"2021","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34575268","citation_count":11,"is_preprint":false},{"pmid":"36672342","id":"PMC_36672342","title":"Roles of IL-7R Induced by Interactions between Cancer Cells and Macrophages in the Progression of Esophageal Squamous Cell Carcinoma.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36672342","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50010,"output_tokens":8073,"usd":0.135563},"stage2":{"model":"claude-opus-4-6","input_tokens":12022,"output_tokens":4407,"usd":0.255427},"total_usd":0.39099,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"Loss-of-function mutations in IL7R cause T(-)B(+)NK(+) SCID, demonstrating that IL-7Rα signaling is required for human T-cell development but not NK-cell development, and that the T-cell (but not NK-cell) defect in X-linked SCID results from inactivation of IL-7Rα signaling.\",\n      \"method\": \"Genetic identification of IL7R mutations in SCID patients; comparison of T, B, NK cell phenotypes across SCID genotypes\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — definitive loss-of-function human genetics with clear cellular phenotype; foundational paper with >600 citations\",\n      \"pmids\": [\"9843216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A SNP (rs6897932) in alternatively spliced exon 6 of IL7R influences the ratio of soluble to membrane-bound IL-7Rα isoforms by disrupting an exonic splicing silencer, thereby affecting IL-7R signaling levels and multiple sclerosis risk.\",\n      \"method\": \"Functional SNP analysis; alternative splicing assays measuring soluble vs. membrane-bound isoform ratios\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional splicing assay with replicated genetic association across four independent cohorts\",\n      \"pmids\": [\"17660817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Somatic gain-of-function IL7R mutations in T-ALL (mostly in exon 6) introduce unpaired cysteines in the extracellular juxtamembrane-transmembrane region, promoting de novo intermolecular disulfide bonds between mutant IL-7Rα subunits and driving constitutive JAK1 signaling independently of IL-7, γc, or JAK3, leading to cell transformation and tumor formation.\",\n      \"method\": \"Biochemical assays (disulfide bond formation), signaling assays (JAK1 phosphorylation), cell transformation assays, mutagenesis (cysteine requirement), tumor formation in mice\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution, mutagenesis, and in vivo transformation assays in a single landmark study; replicated by Shochat et al. same year\",\n      \"pmids\": [\"21892159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Gain-of-function IL7R mutations in pediatric B- and T-ALL cause either S185C extracellular substitution or transmembrane domain insertions/deletions; the cysteine is essential for constitutive receptor activation; in B-cell precursor leukemias, mutant IL-7Rα forms a functional receptor with CRLF2 for TSLP signaling; these mutations confer cytokine-independent growth.\",\n      \"method\": \"Biochemical activation assays, cytokine-independent growth assays, mutagenesis confirming cysteine requirement, functional CRLF2 co-receptor assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biochemical and functional assays with mutagenesis; independent replication of Zenatti et al.\",\n      \"pmids\": [\"21536738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Soluble IL-7Rα (sIL7Rα) has moderate affinity for IL-7 but does not bind TSLP; sIL7Rα competes with cell-associated IL-7R to reduce excessive IL-7 consumption, thereby enhancing IL-7 bioactivity when cytokine is limited; sIL7Rα also diminishes CD95 and SOCS1 expression during IL-7 signaling and potentiates homeostatic expansion and autoimmune encephalomyelitis in murine models.\",\n      \"method\": \"Binding affinity assays (sIL7Rα vs. IL-7/TSLP), in vitro signaling assays, murine homeostatic expansion models, EAE model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro and in vivo assays; direct binding and functional measurements\",\n      \"pmids\": [\"23610432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CPSF1 (cleavage and polyadenylation specificity factor 1) binds to a consensus polyadenylation signal (AAUAAA) in intron 6 of IL7R downstream of the exon 6 5' splice site and represses exon 6 inclusion; competing mRNA splicing and polyadenylation regulate the ratio of soluble to membrane-bound IL7R isoforms.\",\n      \"method\": \"RNA affinity chromatography/mass spectrometry to identify trans-acting factors; CPSF1 knockdown splicing assays; mutagenesis of polyadenylation signal\",\n      \"journal\": \"RNA (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical identification of trans-acting factor combined with mutagenesis and functional knockdown assays\",\n      \"pmids\": [\"23151878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The RNA helicase DDX39B is a potent activator of IL7R exon 6 splicing (promoting membrane-bound isoform) and repressor of soluble IL7R production; a genetic variant in the 5' UTR of DDX39B reduces its translation and shows strong genetic and functional epistasis with IL7R exon 6 allelic variants to increase MS risk.\",\n      \"method\": \"RNA helicase functional assays, genetic association analysis, translational reporter assays, splicing minigene assays, epistasis analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional splicing mechanistic demonstration with genetic epistasis validated across multiple approaches\",\n      \"pmids\": [\"28340352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IL-7 stimulation induces clathrin-mediated endocytosis of CD127 (IL-7Rα) in primary human CD8 T cells through a process dependent on lipid-raft formation and dynamin activity; internalized CD127 traffics from early endosomes (EEA1+) to late endosomes (RAB7+) and is subsequently degraded by the proteasome (20S subunit co-localization), providing a negative feedback mechanism on IL-7 signaling.\",\n      \"method\": \"Confocal microscopy with endosomal markers, inhibitor studies (clathrin, dynamin, lipid rafts), proteasome inhibition assays in primary human CD8 T cells\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct live-cell imaging and functional inhibitor studies with multiple orthogonal markers; mechanistically complete pathway\",\n      \"pmids\": [\"26272555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IL-7Rα undergoes polyglutamylation catalyzed by TTLL4 and TTLL13 in common helper-like innate lymphoid progenitors; this polyglutamylation triggers STAT5 activation to initiate Sall3 transcription factor expression, driving ILC3 differentiation; CCP2 deglutamylase reverses this modification, and IL-7Rα E446A mutation reduces Sall3 expression and ILC3 numbers.\",\n      \"method\": \"Enzymatic assays identifying TTLL4/TTLL13 as writers and CCP2 as eraser; IL-7Rα E446A knockin mouse; ILC3 quantification; STAT5 phosphorylation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — PTM writer/eraser identification with mutagenesis knockin mouse and downstream signaling readout\",\n      \"pmids\": [\"28794449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Selective disruption of the Y449xxM motif of IL-7Rα (IL-7Rα(449F) knock-in mice) prevents IL-7-mediated T- and B-lymphocyte transformation in transgenic IL-7 and Eμ-myc models, and decreases B-cell viability in bone marrow progenitors; this demonstrates that IL-7Rα Y449 signaling is specifically required for lymphocyte transformation and survival signaling.\",\n      \"method\": \"Knock-in mouse model (IL-7Rα Y449F); crossing with transgenic IL-7 and Eμ-myc lymphomagenesis models; survival/viability assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — targeted knock-in mutagenesis with in vivo genetic epistasis in lymphomagenesis models\",\n      \"pmids\": [\"20440272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IL-7R is essential for leukemia-initiating cell (LIC) activity in T-ALL: IL-7Rα-deficient hematopoietic progenitors transduced with constitutively active Notch1 fail to generate leukemia in vivo; IL-7R expression marks T-ALL cells with LIC potential; impaired IL-7R signaling hampers engraftment of patient-derived T-ALL xenografts; IL-7R-dependent LIC activity extends to B-ALL.\",\n      \"method\": \"Loss-of-function (Il7r-deficient mice), Notch1-induced T-ALL transplantation model, patient-derived xenografts, limiting-dilution transplantation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined cellular phenotype, multiple in vivo models including patient-derived xenografts\",\n      \"pmids\": [\"31530562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Overexpression of wild-type IL-7Rα (without mutational activation) in mouse models drives thymocyte self-renewal, thymus hyperplasia, and fatal T-ALL with activation of JAK/STAT, PI3K/Akt/mTOR, and Notch signaling, with frequent PI3K/Akt hyperactivation and Bcl-2 upregulation; tumors remain sensitive to IL-7R-mediated signaling inhibitors.\",\n      \"method\": \"Tetracycline-inducible Il7r transgenic mice; Rosa26 IL7R knockin mice; pharmacological inhibitors (ruxolitinib, AZD1208, dactolisib, palbociclib, venetoclax); transcriptional profiling\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent mouse gain-of-function models with mechanistic signaling characterization and pharmacological validation\",\n      \"pmids\": [\"33970999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IL-7/IL-7Rα signaling maintains telomere integrity via regulation of POT1 (protection of telomere 1) expression; withdrawal of IL-7/IL-7Rα signaling diminishes POT1 protein synthesis, leading to telomere erosion, chromosomal anomalies (including Robertsonian translocations), and p53 pathway activation in developing T cells.\",\n      \"method\": \"IL-7Rα(null)p53(null) double-knockout mice; molecular analysis of POT1 expression; chromosomal and telomere analyses in thymic lymphomas; IL-7 withdrawal in IL-7-dependent p53(null) cells\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic double-KO model with molecular mechanistic follow-up (POT1 expression) and cellular phenotype\",\n      \"pmids\": [\"22281704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IL7R interacts physically with CXCR4 to recruit BCR-ABL1 and JAK kinases in proximity, forming a molecular platform for BCR-ABL1-induced transformation in Ph+ ALL; BCR-ABL1 kinase inhibitor treatment elevates IL7R expression enabling cytokine-dependent survival; anti-IL7R antibody treatment prevents leukemia development in xenotransplantation models.\",\n      \"method\": \"Co-immunoprecipitation of IL7R/CXCR4 interaction; signaling assays; BCR-ABL1 inhibitor experiments; patient-derived xenograft models with anti-IL7R antibody\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP establishing physical interaction combined with in vivo xenograft validation\",\n      \"pmids\": [\"32581241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IL-7R signaling contributes to thymic T regulatory (Treg) cell development: mice doubly deficient in IL-2Rβ and IL-7Rα lack CD4+Foxp3+ Tregs to the same extent as γc-deficient mice; IL-7R signaling is also required for peripheral survival of CD4+Foxp3low cells in IL-2Rβ-deficient mice.\",\n      \"method\": \"IL-2Rβ/IL-7Rα double-knockout mice; thymic reconstitution experiments; Foxp3+ Treg quantification\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic double-KO with epistasis and reconstitution experiments establishing pathway hierarchy\",\n      \"pmids\": [\"18566388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IL-7Rα is expressed on fetal monocytes and is required for tissue-resident macrophage (trMac) development; blockade of IL-7R function during late gestation specifically impairs establishment of fetal-derived trMacs in vivo; IL-7Rα surface expression is dynamically upregulated upon transition from fetal monocyte to macrophage within fetal tissues.\",\n      \"method\": \"Il7r-Cre lineage tracing; IL-7R blockade in vivo during late gestation; fetal monocyte in vitro differentiation; IL-7Rα surface expression tracking across fetal development\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo lineage tracing with functional blockade experiments defining IL-7Rα role in myeloid development\",\n      \"pmids\": [\"31332039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Antibody B12 against human IL-7Rα impairs IL-7/IL-7R-mediated signaling, is rapidly internalized and traffics to the lysosome upon binding, sensitizes T-ALL cells to dexamethasone, induces NK-mediated ADCC in vitro, and delays T-cell leukemia development in vivo; an B12-MMAE antibody-drug conjugate shows increased leukemia cell killing.\",\n      \"method\": \"Phage-display antibody generation; signaling assays; confocal microscopy of receptor internalization/lysosomal trafficking; in vitro ADCC assays; in vivo xenograft models; ADC efficacy assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays including live imaging of internalization and in vivo validation\",\n      \"pmids\": [\"30850736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Anti-IL-7Rα monoclonal antibodies (two distinct epitopes shown by crystal structures) mediate ADCC-dependent and independent therapeutic efficacy against T-ALL patient-derived xenografts in vivo; relapsed T-ALL cells display elevated IL-7Rα expression and remain sensitive to anti-IL7Rα MAb treatment.\",\n      \"method\": \"Crystal structures of MAb-IL-7Rα complexes; ADCC assays with PDX cells; in vivo xenograft models (minimal residual and established disease)\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures combined with in vivo functional validation\",\n      \"pmids\": [\"31439943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The IL-7Rα antagonist antibody lusvertikimab (LUSV) reduces ALL burden in xenograft models via a dual mechanism: direct IL-7R antagonism and macrophage-mediated antibody-dependent cellular phagocytosis (ADCP); ADCP levels correlate with CD127 surface expression and with in vivo leukemia burden reduction.\",\n      \"method\": \"Patient-derived xenograft (PDX) models; ADCP assays; CD127 expression correlation analysis; combination with polychemotherapy in phase 2-like PDX study\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dual mode of action established with in vitro ADCP and in vivo PDX validation\",\n      \"pmids\": [\"38518105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD53 physically interacts with IL-7R (co-immunoprecipitation and proximity ligation) and promotes IL-7Rα surface expression; loss of CD53 reduces IL-7Rα surface expression and diminishes PI3K and JAK/STAT signaling in prepro- and pro-B cells, leading to increased B cell apoptosis and reduced B lymphopoiesis.\",\n      \"method\": \"Co-immunoprecipitation; proximity ligation assay; CD53-deficient mice; flow cytometry of IL-7Rα surface expression; signaling assays (PI3K, JAK/STAT)\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP and proximity ligation establishing physical interaction with clean KO phenotype and signaling readout\",\n      \"pmids\": [\"31748347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"JAK1 (associated with IL-7Rα) mediates signaling from gain-of-function mutant IL-7Rα; JAK1/2 inhibitor ruxolitinib inhibits ligand-independent signaling from mutant IL-7Rα and induces cell death in vitro and reduces leukemic burden in vivo; BCL-2 is an anti-apoptotic downstream mediator of IL-7R survival signaling and venetoclax (BCL-2 inhibitor) shows activity against mutant IL-7Rα-transformed cells.\",\n      \"method\": \"In vitro signaling assays with ruxolitinib; in vivo mouse leukemia model with ruxolitinib treatment; venetoclax in vitro and combination in vivo assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection with in vitro and in vivo validation establishing JAK1 and BCL-2 as downstream effectors\",\n      \"pmids\": [\"29854301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In lymphatic endothelial cells, IL-7Rα signaling supports lymphatic drainage; endothelial-specific deletion of IL-7Rα impairs lymphatic drainage and increases edema during skin inflammation, while systemic IL-7 treatment exacerbates edema and immune cell infiltration despite increased drainage, showing that IL-7Rα's pro-inflammatory effects on immune cells override anti-inflammatory drainage effects.\",\n      \"method\": \"Endothelial-specific IL-7Rα knockout mice (IL-7RαΔEC); IL-7 administration to wild-type mice; IL-7Rα blocking antibody treatment; psoriasis-like inflammation model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean cell-type-specific KO with defined functional phenotype; single study\",\n      \"pmids\": [\"31406267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IL-7Rα down-regulation in zebrafish activates JAK/STAT signaling leading to apoptosis in oligodendrocytes; IL-7R is essential for myelination in embryonic and larval zebrafish.\",\n      \"method\": \"Targeted knockdown of IL-7R in zebrafish; demyelination model; JAK/STAT signaling assays; apoptosis analysis in oligodendrocytes\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — zebrafish KD with defined cellular phenotype; single study with moderate mechanistic follow-up\",\n      \"pmids\": [\"28415697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In IL-7-stimulated CD8 T cells activated with IL12, enhanced IL-7Rα expression is critical for antitumor immunity in lymphodepleted recipients; elevated IL7Rα expression confers responsiveness to host IL-7 (not IL-15) for maximal engraftment of effector CD8 T cells.\",\n      \"method\": \"IL7Rα-deficient T cells; IL12 activation conditioning; adoptive transfer into lymphodepleted mice; antitumor efficacy assays\",\n      \"journal\": \"Cancer immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with defined in vivo phenotype; single study\",\n      \"pmids\": [\"26297711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In IL7Rα-deficient T cells from Schimke immuno-osseous dysplasia (SIOD) patients, the IL7R promoter is hypermethylated (CpG methylation), leading to absent IL7Rα protein and mRNA and unresponsiveness to IL-7 stimulation; no pathogenic mutations were found in IL7R exons, implicating epigenetic silencing as the mechanism.\",\n      \"method\": \"IL7Rα protein and mRNA measurement; IL-7 stimulation assays; CpG methylation analysis of IL7R promoter; Sanger sequencing of IL7R exons\",\n      \"journal\": \"Clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mechanistic demonstration of epigenetic regulation; single study in patient samples\",\n      \"pmids\": [\"26499378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IL7R overexpression in esophageal squamous cell carcinoma promotes cancer cell survival; HDAC inhibitor apicidin downregulates IL7R by inducing acetylation of FOXO1, which then acts as a transcriptional repressor at the IL7R promoter, accompanied by decreased active histone modifications (ChIP assay).\",\n      \"method\": \"HDAC inhibitor (apicidin) treatment; ChIP assay for acetylated FOXO1 at IL7R promoter; histone modification analysis; IL7R knockdown anti-oncogenic effect assays\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-based mechanistic demonstration of FOXO1-mediated IL7R transcriptional repression; single study\",\n      \"pmids\": [\"29749437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In monocytes, monocyte surface and soluble IL-7R expression are induced by LPS and strongly associate with allelic carriage of rs6897932 (disease-associated IL7R polymorphism); sIL7R production by monocytes exceeds that of CD4+ T cells; sIL7R expression additionally correlates with DDX39A (a splicing factor) expression.\",\n      \"method\": \"Protein-level genetic regulation analysis; LPS stimulation assays; flow cytometry of surface IL7R; sIL7R ELISA; genotype-protein association in healthy individuals\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct protein-level measurement with genotype-expression association; single study but multiple cell types and methods\",\n      \"pmids\": [\"31594933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Loss of IL7Rα (but not Flk2) intrinsically and essentially impairs generation of tissue-resident lymphoid cells including B1a cells, marginal zone B cells, lung ILC2s, and regulatory T cells; an IL7Rα-deficient environment also selectively impairs reconstitution of these cells by wild-type HSCs, indicating both cell-intrinsic and extrinsic roles.\",\n      \"method\": \"Flk2-Cre and Il7r-Cre lineage tracing; Flk2 and IL7Rα single and double knockout mice; reciprocal transplantation experiments\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined phenotype and reciprocal transplantation; single study\",\n      \"pmids\": [\"35072209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IL-7 treatment of CD4+CD25+CD127+ FoxP3+ T cells induces their phenotypic maturation into classical FoxP3+CD4+CD25hi CD127- regulatory T cells, with increased nuclear FoxP3 accumulation, CD25 upregulation, and concurrent CD127 downregulation in vitro.\",\n      \"method\": \"In vitro IL-7 treatment of sorted T cell populations; flow cytometry of CD127/CD25/FoxP3 expression; nuclear FoxP3 localization assay\",\n      \"journal\": \"Clinical and experimental immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — in vitro phenotypic conversion with functional readout; single lab, single study\",\n      \"pmids\": [\"21413939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"lnc-IL7R (a long noncoding RNA overlapping the 3'UTR of IL7R) suppresses LPS-induced inflammatory response by maintaining trimethylation of histone H3 at lysine 27 (H3K27me3) at the proximal promoters of inflammatory mediators (E-selectin, VCAM-1, IL-6, IL-8); knockdown of lnc-IL7R diminishes H3K27me3 and increases inflammatory gene expression.\",\n      \"method\": \"lnc-IL7R knockdown; ChIP assay for H3K27me3 at inflammatory gene promoters; LPS stimulation with cytokine/adhesion molecule measurement\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-based mechanistic demonstration; single study with two orthogonal methods\",\n      \"pmids\": [\"24723426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IL-7R overexpression in ESCC cells (induced by direct co-culture with macrophages) promotes cancer cell survival and growth via activation of Akt and Erk1/2 signaling pathways; the IL-7/IL-7R axis also promotes ESCC cell migration through the same pathways.\",\n      \"method\": \"Co-culture of ESCC cells with macrophages; cDNA microarray; IL7R overexpression; signaling assays (Akt, Erk1/2 phosphorylation); migration assays\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with defined downstream signaling; single study\",\n      \"pmids\": [\"36672342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Mutant IL7R collaborates with MYC to induce early-onset T-ALL in zebrafish; mutant IL7R alone can induce T-ALL with long latency; T-ALLs co-expressing mutant IL7R and Myc show STAT5 and AKT pathway activation; mutant IL7R increases the frequency of leukemia propagating cells as shown by limiting-dilution transplantation.\",\n      \"method\": \"Stable transgenic zebrafish expressing mutant IL7R and/or Myc; limiting-dilution cell transplantation; signaling assays (STAT5, AKT); apoptosis assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo zebrafish genetic model with mechanistic signaling readout; single study\",\n      \"pmids\": [\"35581375\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IL-7Rα (IL7R) forms a heterodimeric receptor with γc that signals constitutively through JAK1/JAK3 and STAT5/PI3K/Akt pathways to drive T-cell development, survival, and homeostasis; gain-of-function mutations introducing unpaired cysteines in the extracellular juxtamembrane-transmembrane region drive homodimerization and ligand-independent JAK1 signaling in T-ALL, while its Y449 motif specifically supports lymphocyte survival and transformation, and its expression is tightly regulated at the splicing level (exon 6 inclusion/skipping controlling membrane-bound vs. soluble isoform ratios via CPSF1 and DDX39B), at the post-translational level (clathrin/dynamin-mediated endocytosis and proteasomal degradation upon IL-7 binding), and by a novel polyglutamylation modification (by TTLL4/TTLL13, reversed by CCP2) that triggers STAT5 and Sall3-driven ILC3 development.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"IL-7Rα (encoded by IL7R) is the ligand-binding subunit of the IL-7 receptor, essential for T-cell development, B lymphopoiesis, regulatory T-cell generation, innate lymphoid cell differentiation, and tissue-resident macrophage establishment. IL-7Rα pairs with the common γ chain (γc) to signal through JAK1/JAK3–STAT5 and PI3K/Akt pathways; the intracellular Y449 motif is specifically required for lymphocyte survival and transformation, and loss-of-function IL7R mutations cause T(−)B(+)NK(+) SCID [PMID:9843216, PMID:20440272]. Gain-of-function mutations—predominantly introducing unpaired cysteines in the extracellular juxtamembrane-transmembrane region—drive ligand-independent homodimerization and constitutive JAK1 signaling that transforms T- and B-cell progenitors in acute lymphoblastic leukemia [PMID:21892159, PMID:21536738, PMID:31530562]. Receptor availability is tightly controlled at multiple levels: alternative splicing of exon 6 (regulated by CPSF1 and DDX39B) sets the ratio of membrane-bound to soluble isoforms influencing autoimmune disease risk, IL-7 binding triggers clathrin/dynamin-dependent endocytosis and proteasomal degradation, and polyglutamylation by TTLL4/TTLL13 (reversed by CCP2) activates STAT5-Sall3 signaling to direct ILC3 fate [PMID:17660817, PMID:23151878, PMID:28340352, PMID:26272555, PMID:28794449].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"The fundamental question of whether IL-7Rα is required for human lymphocyte development was answered: loss-of-function IL7R mutations cause T(−)B(+)NK(+) SCID, establishing that IL-7Rα signaling is essential for T-cell but dispensable for NK-cell ontogeny.\",\n      \"evidence\": \"Identification of IL7R mutations in SCID patients with defined T/B/NK cell phenotyping\",\n      \"pmids\": [\"9843216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise downstream signaling pathways mediating the T-cell developmental block were not delineated\", \"Whether IL-7Rα contributes to non-lymphoid lineages was unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"A key regulatory question—how IL-7Rα surface expression is controlled—was addressed by demonstrating that alternative splicing of exon 6 governs the ratio of membrane-bound to soluble receptor isoforms, and that a common SNP (rs6897932) disrupting an exonic splicing silencer alters this ratio and confers multiple sclerosis risk.\",\n      \"evidence\": \"Functional splicing assays with minigenes; genetic association replicated across four independent MS cohorts\",\n      \"pmids\": [\"17660817\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-acting splicing factors controlling exon 6 inclusion were unidentified\", \"How soluble IL-7Rα modulates IL-7 bioavailability in vivo was unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"IL-7Rα's role was extended beyond conventional T cells to thymic regulatory T-cell development: double-deficient IL-2Rβ/IL-7Rα mice phenocopy γc deficiency for Foxp3+ Treg loss, establishing IL-7Rα as a non-redundant contributor to Treg ontogeny.\",\n      \"evidence\": \"IL-2Rβ/IL-7Rα double-knockout mice with thymic reconstitution and Foxp3+ Treg quantification\",\n      \"pmids\": [\"18566388\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IL-7Rα acts at the commitment or survival stage of Treg development was not resolved\", \"The relative quantitative contributions of IL-2 vs. IL-7 signaling to Treg generation remained unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The specific intracellular signaling motif responsible for IL-7Rα's pro-survival and transforming activity was identified: Y449F knock-in mice showed that the Y449 motif is required for IL-7-driven lymphocyte transformation and bone marrow B-cell survival.\",\n      \"evidence\": \"IL-7Rα Y449F knock-in mice crossed with transgenic IL-7 and Eμ-myc lymphomagenesis models\",\n      \"pmids\": [\"20440272\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific downstream effectors (STAT5 vs. PI3K) are recruited to Y449 in vivo to mediate transformation was not separated\", \"Whether Y449 is sufficient or merely necessary for transformation was unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The oncogenic mechanism of IL7R mutations in T-ALL and B-ALL was elucidated: gain-of-function mutations introduce unpaired cysteines that promote receptor homodimerization via de novo disulfide bonds, driving constitutive JAK1 signaling independent of IL-7, γc, or JAK3; in B-ALL, mutant IL-7Rα partners with CRLF2 for TSLP signaling.\",\n      \"evidence\": \"Disulfide bond biochemistry, cysteine requirement by mutagenesis, cell transformation assays, tumor formation in mice (two independent studies)\",\n      \"pmids\": [\"21892159\", \"21536738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for how a single cysteine substitution promotes homodimerization was not resolved at atomic resolution\", \"Cooperating genetic events in full leukemogenesis were only partially characterized\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Two regulatory layers of IL-7Rα were mechanistically defined: CPSF1 was identified as a trans-acting factor repressing exon 6 inclusion via intronic polyadenylation competition, and IL-7Rα signaling was shown to maintain telomere integrity through POT1 expression.\",\n      \"evidence\": \"RNA affinity chromatography/mass spectrometry with CPSF1 knockdown for splicing; IL-7Rα-null/p53-null double-KO mice with POT1 and telomere analyses\",\n      \"pmids\": [\"23151878\", \"22281704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Additional trans-acting splicing factors beyond CPSF1 were not identified\", \"Whether POT1 regulation is direct (transcriptional) or indirect via STAT5 was not determined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The biological function of soluble IL-7Rα was clarified: sIL-7Rα binds IL-7 with moderate affinity, competes with membrane-bound receptor to preserve IL-7 bioavailability under limiting conditions, and potentiates autoimmune pathology in vivo.\",\n      \"evidence\": \"Binding affinity measurements; murine homeostatic expansion and EAE models with sIL-7Rα administration\",\n      \"pmids\": [\"23610432\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological concentrations of sIL-7Rα in disease states were incompletely characterized\", \"Whether sIL-7Rα functions as agonist or antagonist may depend on tissue IL-7 concentration, which was not fully mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The negative feedback mechanism for IL-7Rα surface expression was mapped: IL-7 binding triggers clathrin-dependent, dynamin-dependent internalization through lipid rafts, with trafficking from early to late endosomes and proteasomal degradation.\",\n      \"evidence\": \"Confocal microscopy with endosomal markers (EEA1, RAB7, 20S proteasome) and pharmacological inhibitors in primary human CD8 T cells\",\n      \"pmids\": [\"26272555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin ligase(s) targeting internalized IL-7Rα for proteasomal degradation were not identified\", \"Whether lysosomal degradation also contributes was not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"DDX39B was established as a second major trans-acting regulator of IL7R splicing: it promotes exon 6 inclusion (membrane-bound isoform), and a DDX39B 5′ UTR variant reducing its translation shows strong epistasis with the IL7R exon 6 SNP for MS susceptibility.\",\n      \"evidence\": \"Splicing minigene assays; translational reporter assays; genetic epistasis analysis\",\n      \"pmids\": [\"28340352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DDX39B acts directly on IL7R pre-mRNA or through an intermediary was not biochemically resolved\", \"Additional helicase cofactors in the splicing complex were not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A novel post-translational modification—polyglutamylation—was discovered on IL-7Rα: TTLL4/TTLL13 catalyze this modification in innate lymphoid progenitors, triggering STAT5 activation and Sall3-driven ILC3 differentiation, while CCP2 reverses it.\",\n      \"evidence\": \"Enzymatic writer/eraser identification; IL-7Rα E446A knock-in mouse with reduced ILC3 numbers and Sall3 expression\",\n      \"pmids\": [\"28794449\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The precise glutamate residues modified and the stoichiometry of polyglutamylation were not fully mapped\", \"How polyglutamylation mechanistically enhances JAK/STAT signaling was not determined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Pharmacological dissection confirmed that gain-of-function IL-7Rα mutants signal through JAK1 and upregulate BCL-2 as a critical survival effector: ruxolitinib blocks mutant signaling and venetoclax kills mutant-transformed cells.\",\n      \"evidence\": \"In vitro signaling assays and in vivo leukemia models with JAK1/2 and BCL-2 inhibitors\",\n      \"pmids\": [\"29854301\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether drug resistance mechanisms emerge upon prolonged JAK inhibition was not tested\", \"Combination synergy was not systematically optimized\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Multiple studies converged to define IL-7Rα's roles beyond classical lymphopoiesis and its therapeutic targetability: IL-7Rα marks and is required for leukemia-initiating cells in T-ALL; it is expressed on fetal monocytes and required for tissue-resident macrophage development; CD53 physically interacts with IL-7Rα to stabilize its surface expression; and anti-IL-7Rα antibodies show therapeutic efficacy via signaling blockade, ADCC, and internalization-based drug delivery.\",\n      \"evidence\": \"Il7r-KO Notch1 T-ALL model and PDX transplantation; Il7r-Cre lineage tracing with gestational blockade; Co-IP/PLA for CD53 interaction with CD53-KO mice; phage-display antibodies with crystal structures, ADCC assays, and xenograft models\",\n      \"pmids\": [\"31530562\", \"31332039\", \"31748347\", \"30850736\", \"31439943\", \"32581241\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IL-7Rα's LIC-maintaining role is signaling-dependent or expression-level-dependent is not fully separated\", \"The structural basis for CD53-mediated stabilization of IL-7Rα at the membrane is unknown\", \"Optimal therapeutic antibody format (naked vs. ADC vs. bispecific) is not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Overexpression of wild-type IL-7Rα—even without activating mutations—was shown to be sufficient for thymocyte self-renewal and T-ALL development, with activation of JAK/STAT, PI3K/Akt/mTOR, and Notch pathways.\",\n      \"evidence\": \"Two independent inducible IL7R transgenic mouse models with pharmacological pathway inhibition\",\n      \"pmids\": [\"33970999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether wild-type IL-7Rα overexpression requires IL-7 ligand for transformation or can signal ligand-independently at high density is not resolved\", \"Cooperating mutations arising during leukemogenesis were not fully catalogued\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"IL-7Rα's requirement was extended to multiple tissue-resident lymphoid populations (B1a, MZ B, ILC2, Treg) via both cell-intrinsic signaling and extrinsic niche effects, and mutant IL7R was shown to cooperate with MYC in an in vivo zebrafish T-ALL model activating STAT5 and AKT.\",\n      \"evidence\": \"Il7r-Cre and Flk2-Cre lineage tracing with reciprocal transplantation in mice; transgenic zebrafish with limiting-dilution transplantation\",\n      \"pmids\": [\"35072209\", \"35581375\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The molecular nature of the IL-7Rα-dependent extrinsic niche signal is unknown\", \"Whether zebrafish IL7R mutant cooperativity with MYC translates to mammalian models remains to be tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The therapeutic mechanism of anti-IL-7Rα antibody lusvertikimab was defined as dual-acting: direct receptor antagonism plus macrophage-mediated ADCP, with efficacy correlating with CD127 surface density.\",\n      \"evidence\": \"PDX models with ADCP assays and CD127 expression correlation; combination with polychemotherapy\",\n      \"pmids\": [\"38518105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Patient selection biomarkers beyond CD127 expression are not established\", \"Mechanisms of resistance to anti-IL-7Rα therapy are undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic structure of full-length IL-7Rα homodimers formed by gain-of-function cysteine mutations, the identity of ubiquitin ligases mediating post-endocytic degradation, the precise mechanism by which polyglutamylation enhances JAK/STAT activation, and whether soluble IL-7Rα is agonistic or antagonistic in different tissue microenvironments.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length structural model of mutant IL-7Rα homodimer\", \"Ubiquitin ligase(s) for IL-7Rα degradation not identified\", \"Mechanistic link between polyglutamylation and STAT5 activation unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 3, 8]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [13, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 5, 6, 7, 19]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 4, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 3, 8, 9, 11, 20]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 14, 15, 27]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 8, 15, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 3, 10, 11, 13, 31]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9, 20]}\n    ],\n    \"complexes\": [\n      \"IL-7R (IL-7Rα/γc heterodimer)\",\n      \"IL-7Rα/CRLF2 heterodimer\"\n    ],\n    \"partners\": [\n      \"IL2RG\",\n      \"JAK1\",\n      \"JAK3\",\n      \"CRLF2\",\n      \"CD53\",\n      \"CXCR4\",\n      \"CPSF1\",\n      \"DDX39B\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}